Anaspec mog The mog35-55 peptide is a critical research tool in understanding demyelinating diseases, most notably multiple sclerosis (MS). This specific peptide fragment, derived from the Myelin Oligodendrocyte Glycoprotein (MOG), is known to induce experimental autoimmune encephalomyelitis (EAE) in animal models. EAE is widely recognized as the most common and relevant animal model for MS, sharing many clinical and pathophysiological features with the human disease.Explore high-purityMOG 35–55 peptidefrom peptides&elephants — immunodominant epitope in multiple sclerosis and EAE models, ideal for T cell assays. Researchers utilize the MOG (35-55) peptide to investigate the complex mechanisms underlying autoimmune responses that target the central nervous system's myelin sheath, aiming to uncover pathways for potential therapeutic interventions.
The MOG (35-55) peptide serves as an immunodominant epitope, meaning it elicits a particularly strong immune response. When administered to susceptible animal models, such as mice and rats, it triggers the development of EAE.Citrullinated human and murine MOG35–55 display distinct ... This induced disease is characterized by inflammation, plaque-like demyelination, and neurological deficits that often manifest as relapsing-remitting episodes, mirroring the progression seen in human MSProducts are chemical reagents for research use only and are not intended for human use. We do not sell to patients.. The ability of MOG (35-55) to reliably induce these symptoms makes it invaluable for studying the cellular and molecular events involved in myelin destruction and the subsequent functional impairments.Human (MOG 1-125) and (MOG-35-55) Myelin ...
The MOG protein itself is a minor component of the central nervous system's myelin, but it plays a significant role in immune-mediated demyelinating disorders. The MOG (35-55) peptide represents a key region of this protein that is recognized by self-reactive T cells. By studying how the immune system responds to this specific peptide, researchers can gain insights into the breakdown of immune tolerance that leads to autoimmune attacks on myelin. This knowledge is crucial for developing strategies that can suppress or modulate these autoreactive immune responses.
The use of the MOG (35-55) peptide in research extends beyond simply modeling diseaseMOG (35-55) human – MEVGWYRPPFSRVVHLYRNGK. Scientists are exploring various approaches based on this peptide to develop new therapeutic strategies for MS. For instance, some research investigates the potential of modified MOG peptides, such as those conjugated with mannan (OM-MOG35-55), to suppress antigen-specific T cell responses.Myelin Oligodendrocyte Glycoprotein (MOG)35-55 Mannan ... These immunomodulatory treatments aim to re-educate the immune system and prevent it from attacking myelinProteins andPeptides MOG [35-55]Peptide(Rat) · 350275 · Brand · Description · Application · Reactivity · Photos · 歡迎填寫資料獲得亞旭第一手資訊. Δ.. Furthermore, the MOG (35-55) peptide is used in assays to evaluate T cell responses, study antibody production, and screen potential therapeutic compounds for their efficacy in treating or preventing demyelination.
While the MOG (35-55) peptide is a widely adopted tool, variations in its application and the species used can influence experimental outcomes作者：MOGIEAE Model—Myelin Oligodendrocyte Glycoprotein (MOG 35-55), 25 mg. Purified myelin oligodendrocyte glycoprotein (MOG) for MOG-induced EAE models in mouse and rat. Multiple .... Researchers often specify whether they are using mouse, rat, or human sequences of the MOG (35-55) peptide, as minor differences in amino acid sequences can affect immunogenicityMOG (35-55) (mouse, rat) (trifluoroacetate salt). Additionally, the purity of the peptide and its formulation (e.g., as a trifluoroacetate salt) are critical factors for consistent and reproducible results in EAE induction and other immunological studies. The precise amount of peptide needed to induce EAE can also vary, necessitating careful titration in experimental designs.
In conclusion, the MOG (35-55) peptide is a fundamental component in the study of multiple sclerosis and related demyelinating diseases. Its capacity to reliably induce EAE in animal models provides a vital platform for dissecting the pathogenesis of these conditions and for the preclinical evaluation of novel immunotherapiesMOG (35-55) | Neuronal Metabolism Peptides and .... Continued research utilizing this peptide promises to deepen our understanding of autoimmune neurological disorders and drive the development of effective treatments作者：MOGIEAE Model—Myelin Oligodendrocyte Glycoprotein (MOG 35-55), 25 mg. Purified myelin oligodendrocyte glycoprotein (MOG) for MOG-induced EAE models in mouse and rat. Multiple ....
Join the newsletter to receive news, updates, new products and freebies in your inbox.